Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin producing beta cells are destroyed. Antigen-based immunotherapy provides an approach to selectively tolerize pathogenic beta cell-specific T cells, while leaving the remainder of the immune system intact. In this article, we discuss our group's experience in defining the parameters that impact the efficacy of beta cell antigen "vaccination" for the prevention and treatment of T1D.
Wang
Bo
B
Department of Microbiology and Immunology, University of North Carolina, Mary Ellen Jones Bldg., Room 635, Campus Box 7290, Chapel Hill, North Carolina, 27599-7290, USA.
Tisch
Roland
R
D000818:Animals; D001324:Autoantigens / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000628:therapy*; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D016233:Immunotherapy, Active / Q000379:methods*; D007328:Insulin / Q000276:immunology; D050417:Insulin-Secreting Cells / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology
D001324:Autoantigens; D007328:Insulin; D010446:Peptide Fragments; C097877:insulin B (9-23); C439756:GAD65 (217-236); D005968:Glutamate Decarboxylase